LumiraDx™

Join us at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo

Booth #4821

Clinical Performance of the LumiraDx Platform and Intended Applications

Wednesday, July 27, 2:45pm-3:45pm
Exhibit Hall Theater 3

Paul K. Drain
MD, MPH, FIDSA
Associate Professor of Medicine, Allergy and Infectious Disease
University of Washington, International Clinical Research Center

Brian DuChateau
Ph.D., D(ABMLI)
VP of Clinical and Scientific Affairs, LumiraDx



Come see LumiraDx at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo

LumiraDx™

The LumiraDx SARS-CoV-2 Ag test and the LumiraDx SARS-CoV-2 Ab test have not been cleared or approved by FDA, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. The LumiraDx SARS-CoV-2 Ag test has been authorized only for the detection of proteins from SARS-CoV-2. The LumiraDx SARS-CoV-2 Ab test has been authorized only for detecting the presence of total antibodies to SARS-CoV-2. They have not been authorized for use to detect any other viruses or pathogens. The emergency use of these products are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

S-COM-ART-02611 R1 2022/06